Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations of returning to an upward cycle by 2026 and benefiting from the launch of oncology and metabolic innovative products starting in 2027 [1] Group 1: Financial Projections - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to enhance the company's profits over the next 3-5 years [1] - Haitong International has adjusted the revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, RMB 28.9 billion, and RMB 30.6 billion respectively [5] - The net profit forecasts for FY25, FY26, and FY27 have been adjusted to RMB 4.4 billion, RMB 4.6 billion, and RMB 5.3 billion respectively [6] Group 2: Research and Development Capabilities - CSPC Pharmaceutical Group has completed seven external cooperation transactions in the past two years, with total upfront payments of $1.71 billion and potential milestone amounts exceeding $30 billion [1] - The company has established a strong research and development platform, evidenced by collaborations with AstraZeneca, indicating its global influence and value [1] - The company is recognized for its small nucleic acid platform, which covers popular liver delivery targets and is ahead of domestic peers in development [2] Group 3: Product Pipeline and Market Potential - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential as a best-in-class product [3] - The company has initiated a Phase III clinical trial for SYS6010 in China and plans to advance global Phase III trials within the year [3] - CSPC has received the first clinical approval in China for its in vivo CAR-T product, SYS6055, which is expected to have advantages in cost, accessibility, and immediacy compared to traditional CAR-T products [4]

Macro and Strategy Research - The US economy is expected to maintain resilience due to Trump's tax cuts and tech capital expenditures, with the Fed likely to keep interest rates unchanged amid mixed signals on employment and inflation [2] - The Eurozone is experiencing weak recovery, with uncertainties stemming from geopolitical issues, particularly related to Greenland, which may affect economic stability [2] Domestic Economy - China's GDP growth in Q4 2025 slowed due to high base effects, but overall growth targets were met, with a stronger supply than demand and external demand outpacing internal demand [3] - High-frequency data suggests that exports may remain strong in early 2026, supported by tax policy adjustments and semiconductor industry performance, while domestic consumption faces challenges [3] - Investment is expected to gradually recover, driven by manufacturing and infrastructure investments, although the real estate sector remains cautious [3] Domestic Policy Environment - The People's Bank of China announced a package of structural monetary policies, indicating potential for further rate cuts and reserve requirement ratio reductions [3] - Fiscal policies, including interest subsidies and risk-sharing measures, are aimed at stimulating economic activity and improving corporate financing willingness [4] Fixed Income Research - The bond market has shown a strong oscillation, with the central bank injecting over 9 trillion yuan into the market, and MLF operations reaching 900 billion yuan [6] - The issuance of local government bonds has lengthened in duration, reflecting strategies to take advantage of low interest rates [6] - The bond market is expected to continue its oscillation, with inflation and monetary policy being key factors influencing market dynamics [7] Industry Research - The pharmaceutical industry is witnessing significant collaborations, such as the strategic partnership between CSPC Pharmaceutical and AstraZeneca for innovative long-acting peptide drug development [8] - The SW Pharmaceutical sector index shows a TTM P/E ratio of 51.60, with a valuation premium of 259% over the CSI 300 index [9] - Investment opportunities are identified in innovative drugs, CXO, and upstream life sciences, with a focus on AI applications in healthcare and pharmaceuticals [9]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].

Core Viewpoint - The approval of SYS6055 injection by the National Medical Products Administration (NMPA) marks a significant advancement for the company, as it is the first domestically approved in vivo CAR-T product for clinical trials in China [1] Group 1: Product Development - SYS6055 is developed to generate CAR-T cells targeting CD19 directly in vivo using a lentiviral vector, which allows for specific identification and elimination of target cells [1] - The product demonstrates significant tumor suppression effects and good safety profiles in preclinical studies, indicating its potential as a better treatment option for patients with B-cell lymphomas [1] Group 2: Market Potential - Compared to traditional CAR-T products, SYS6055 offers potential advantages in terms of cost, accessibility, and immediacy [1] - The approved clinical indication is for relapsed/refractory aggressive B-cell lymphoma, with potential applications for other CD19-positive B-cell malignancies and autoimmune diseases, highlighting its high clinical development value [1]